FDA PCAC July 2026: What to Expect at the July 23–24 Peptide Compounding Hearing

FDA PCAC July 2026 convenes on July 23–24 at the agency's White Oak campus, where the Pharmacy Compounding Advisory Committee will formally evaluate seven peptides — BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon — for potential inclusion on the Section 503A Bulk Drug Substances List. For researchers, compounding pharmacies, and laboratories tracking these compounds, the hearing is the most concrete regulatory milestone since the docket opened, and it has generated more search interest than any single event covered on this site to date.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 at FDA White Oak to vote on whether BPC-157, KPV, TB-500, MOTS-C, Emideltide/DSIP, Semax, and Epitalon should be added to the 503A Bulk Drug Substances List; the meeting is webcast publicly, the public comment docket (FDA-2025-N-6895) closes July 22, 2026, and the committee's recommendation is advisory only — final rulemaking authority remains with the FDA.

TL;DR:

Day 1 (July 23, 8:00 a.m.–4:30 p.m. ET): BPC-157, KPV, TB-500, and MOTS-C bulk substances are reviewed.
Day 2 (July 24, 8:00 a.m.–3:50 p.m. ET): Emideltide (DSIP), Semax, and Epitalon bulk substances are reviewed.
Public docket FDA-2025-N-6895 accepts written comments through 11:59 p.m. ET on July 22, 2026 via Regulations.gov.
A free live webcast will be posted in the meeting's Event Materials section no later than two business days beforehand.
The PCAC vote is a recommendation, not a final rule — FDA retains sole authority over 503A Bulks List additions.

What was announced

The FDA established a public docket and formal meeting notice for the July 23–24, 2026 session of the Pharmacy Compounding Advisory Committee, publishing the announcement in the Federal Register in April 2026. The committee's task is narrow but consequential: determine whether each nominated bulk drug substance meets the statutory criteria under section 503A of the Food, Drug, and Cosmetic Act — historical use in compounding, physical and chemical characterization, and stability data — for inclusion on the list that governs which substances licensed compounding pharmacies may legally use to prepare patient-specific prescriptions.

Seven peptides made the docket. Four are scheduled for Day 1 review: BPC-157, a pentadecapeptide studied for tissue and tendon repair; KPV, an alpha-MSH–derived tripeptide studied for anti-inflammatory activity; TB-500, a thymosin beta-4 fragment studied for angiogenesis and wound models; and MOTS-C, a mitochondria-derived peptide studied in metabolic and insulin-sensitivity research. Three are scheduled for Day 2: Emideltide (also referred to as DSIP), Semax, and Epitalon. Each compound's bulk substance and its acetate salt form are being evaluated as a pair, meaning the committee will effectively issue up to 14 individual determinations across the two days.

Affected compounds

Researchers following any of the seven compounds should expect direct effects on 503A sourcing regardless of which way the committee leans. The full docket, in review order:

BPC-157 (free base and acetate) — see the BPC-157 library profile and the ongoing NCT07437547 Phase 2 trial coverage.
KPV (free base and acetate) — see the KPV library profile.
TB-500 (free base and acetate) — see the TB-500 library profile.
MOTS-C (free base and acetate) — see the MOTS-C library profile.
Emideltide / DSIP (free base and acetate) — see the DSIP library profile.
Semax (free base and acetate) — see the Semax library profile.
Epitalon (free base and acetate) — see the Epitalon library profile.

Each of these compounds already has a dedicated PCAC-focused profile on this site covering its individual preclinical evidence base and current 503A status; this article covers only the mechanics of the hearing itself.

What this changes for research access

The 503A Bulks List is the specific legal mechanism that allows a licensed 503A compounding pharmacy to prepare a bulk drug substance into a patient-specific prescription in the absence of an FDA-approved drug product or USP monograph. A substance placed in "Category 1" is generally treated as eligible for continued nomination and future compounding under defined conditions; a "Category 2" designation signals FDA staff have identified safety, effectiveness, or characterization concerns significant enough to weigh against inclusion. Neither category is a ban on research use — laboratories operating outside patient-dispensing contexts are governed by separate rules — but a negative PCAC recommendation followed by an adverse final agency decision would narrow the compounding pathway that some research-adjacent supply chains currently rely on.

Researchers trying to track outcomes across all seven compounds in one place, rather than parsing seven separate FDA dockets, can use the PCAC outcomes tracker, which is being updated as agency materials and committee actions are published.

Timeline and what's next

The public comment period on docket FDA-2025-N-6895 runs through 11:59 p.m. Eastern Time on July 22, 2026, the day before the hearing begins. Individuals who requested to speak at the meeting were to be notified of their scheduling by July 1, 2026. On the hearing dates themselves, FDA will post a free live webcast link in the Event Materials section of the meeting page no later than two business days in advance, and the proceedings will also be captioned and recorded for later access.

It's worth being explicit about what happens after the vote: a PCAC recommendation is advisory. The committee's role is to inform FDA's decision-making, not to issue a binding determination. Following the meeting, FDA reviews the committee's discussion and any additional public comments before proceeding — or not — with formal rulemaking to add or exclude substances from the 503A Bulks List. That process can take months. Researchers should expect a period of regulatory ambiguity between the July hearing and any final published rule, and this site will track and report on formal FDA action as it is issued.

External sources

July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA advisory committee calendar listing
Federal Register: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket — docket FDA-2025-N-6895, comment procedures, and full agenda
Regulations.gov public docket FDA-2025-N-6895 — comment submission portal, open through July 22, 2026

Frequently asked questions

Q: What is the FDA Pharmacy Compounding Advisory Committee (PCAC)?

A: The PCAC is an FDA advisory committee that reviews bulk drug substances nominated for the Section 503A Bulks List and makes non-binding recommendations to the agency on whether each substance meets the statutory criteria for inclusion. Its recommendations inform, but do not replace, FDA's own rulemaking decisions.

Q: When is the July 2026 PCAC hearing and how can researchers watch it?

A: The meeting runs July 23, 2026 from 8:00 a.m. to 4:30 p.m. ET and July 24, 2026 from 8:00 a.m. to 3:50 p.m. ET at FDA's White Oak campus in Silver Spring, Maryland. A free live webcast link will be posted in the meeting's Event Materials section no later than two business days beforehand.

Q: Which peptides are being reviewed at the July 2026 PCAC meeting?

A: Day 1 covers BPC-157, KPV, TB-500, and MOTS-C bulk drug substances. Day 2 covers Emideltide (DSIP), Semax, and Epitalon bulk drug substances. Each compound's free base and acetate salt forms are being considered separately.

Q: Is the PCAC's recommendation from the July 2026 meeting final?

A: No. The PCAC's vote is advisory only. FDA retains sole authority to add or exclude substances from the 503A Bulks List and typically issues its own determination through formal rulemaking sometime after the committee meeting, a process that can take months.

Q: Can researchers still submit public comments before the hearing?

A: Public comments on docket FDA-2025-N-6895 are accepted via Regulations.gov through 11:59 p.m. Eastern Time on July 22, 2026, the day before the hearing begins. Requests to speak at the meeting itself were subject to an earlier registration deadline.

See also:

FDA PCAC July 2026 Full Docket Guide — compound-by-compound breakdown of the evidence base for all seven peptides under review.
FDA PCAC July 2026: 29 Days Out — snapshot of each compound's regulatory standing heading into the hearing.
What Happens If BPC-157 Loses 503A Status? — deeper look at the research-access implications of a Category 1 designation for one of the seven compounds.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.